Methyldopa

CARDIOVASCULAR SYSTEM

Key facts

Methyldopa is an ofp drug catalogued in DrugCentral. It was first approved by the FDA in 1962. DrugCentral lists 6 molecular targets, including ALOX15, KDM4E and FYN. Recorded indications include Hypertensive disorder.

• Approval status: ofp (first approved 1962 by the FDA).
• Molecular targets: ALOX15, KDM4E, FYN and EGFR (6 listed in DrugCentral).
• Indications: Hypertensive disorder.
• ATC code: C02AB01 (Methyldopa).
• Molecular formula: C10H13NO4; molecular weight 211.22 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Hypertensive disorder

Contraindications (38)

• Acute hepatitis
• Acute nephropathy
• Acute pancreatitis
• Anemia
• Angina pectoris
• Anuria
• Autoimmune hemolytic anemia
• Azotemia
• Chronic heart failure
• Cirrhosis of liver
• Dehydration
• Depressive disorder
• Diabetes mellitus
• Disease of liver
• Edema
• Gout
• Hepatic coma
• Hepatic failure
• Hypercalcemia
• Hypercholesterolemia
• Hyperparathyroidism
• Hypertriglyceridemia
• Hyperuricemia
• Hypochloremic alkalosis
• Hypokalemia
• Hypomagnesemia
• Hyponatremia
• Hypovolemia
• Kidney disease
• Neonatal hyperbilirubinemia
• + 8 more

Mechanism & targets

Molecular targets (6)

Target	Gene	Action	Activity
Arachidonate 15-lipoxygenase	ALOX15	unknown	IC50 5.67
Lysine-specific demethylase 4E	KDM4E	unknown	IC50 5.52
Tyrosine-protein kinase Fyn	FYN	unknown	IC50 5.29
Epidermal growth factor receptor	EGFR	unknown	IC50 5.28
Alpha-2A adrenergic receptor	ADRA2A	agonist	—
Aromatic-L-amino-acid decarboxylase	DDC	unknown	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1962-12-20	FDA	—	—

ATC classification

ATC code	Therapeutic hierarchy
C02AB01	CARDIOVASCULAR SYSTEM › ANTIHYPERTENSIVES › ANTIADRENERGIC AGENTS, CENTRALLY ACTING › Methyldopa
C02AB02	CARDIOVASCULAR SYSTEM › ANTIHYPERTENSIVES › ANTIADRENERGIC AGENTS, CENTRALLY ACTING › Methyldopa
C02LB01	CARDIOVASCULAR SYSTEM › ANTIHYPERTENSIVES › ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION › Methyldopa and diuretics in combination

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Foetal exposure during pregnancy	3366.4
Premature baby	3084.7
Premature delivery	2144.2
Exposure during pregnancy	1608.0
Low birth weight baby	1560.8
Maternal exposure during pregnancy	1496.4
Foetal growth restriction	835.2
Atrial septal defect	787.0
Pre-eclampsia	635.7
Patent ductus arteriosus	591.3
Small for dates baby	497.0
Oligohydramnios	410.4

Chemical structure

• Molecular formula: C₁₀H₁₃NO₄
• Molecular weight: 211.22 g/mol
• CAS number: —
• InChIKey: CJCSPKMFHVPWAR-JTQLQIEISA-N
• PubChem CID: 38853

C[C@](N)(CC1=CC(O)=C(O)C=C1)C(O)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Methyldopa used for?

DrugCentral lists the following indications for Methyldopa: Hypertensive disorder.

How does Methyldopa work?

Its molecular targets in DrugCentral include ALOX15, KDM4E, FYN and EGFR.

When was Methyldopa first approved?

Methyldopa was first approved by the FDA in 1962.

What is the chemical formula of Methyldopa?

Methyldopa has the molecular formula C10H13NO4 and a molecular weight of 211.22 g/mol.

Sources

• DrugCentral drug card 1762 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL459 — compound record and bioactivity
• PubChem CID 38853 — chemical identifiers
• DrugBank DB00968 — drug record
• FDA UNII 56LH93261Y — substance identity
• DailyMed: FDA labels for Methyldopa — current prescribing information (label search)
• UniProt B2RXH2 (KDM4E) — target protein
• UniProt P06241 (FYN) — target protein
• UniProt P00533 (EGFR) — target protein
• UniProt P08913 (ADRA2A) — target protein
• UniProt P20711 (DDC) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.